Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study
2022; Elsevier BV; Volume: 3; Issue: 4 Linguagem: Inglês
10.1016/s2666-5247(21)00305-0
ISSN2666-5247
AutoresBurc Barin, Ulus Kasap, Ferda Selçuk, Ender Volkan, Özge Uluçkan,
Tópico(s)Heparin-Induced Thrombocytopenia and Thrombosis
ResumoVaccination is an efficient strategy to control the COVID-19 pandemic. In north Cyprus, vaccine distribution started with CoronaVac followed by BNT162b2, and ChAdOx1 vaccines. An option to obtain a third booster dose with BNT162b2 or CoronaVac was later offered to people fully inoculated with CoronaVac. There are few simultaneous and comparative real-world antibody data for these three vaccines as well as boosters after CoronaVac vaccination. Our study was aimed at evaluating antibody responses after these vaccination schemes.
Referência(s)